Immune cell therapy for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (called iNKT cells) that is designed to find and attack leukemia cells. It's for people whose leukemia has come back or hasn't gone away after standard treatments. The goal is to see if this therapy is safe and can help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have acute myeloid leukemia (AML) that has come back or hasn't responded to at least one round of standard treatment.
- Your leukemia cells must have a specific marker (CD33 or CD70) that the therapy targets.
- You should be in reasonably good health, with adequate organ function (kidneys, liver, heart, lungs).
- You must not have had certain previous treatments (like CAR-T or NK cell therapy targeting CD33 or CD70).
- You must not have active infections like HIV, hepatitis B or C, or certain other viruses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that uses your own immune cells (T cells) that have been changed in the lab to find and attack leukemia cells that have a marker called CD84. It is for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments.
This trial tests a new treatment using immune cells (called natural killer cells) derived from stem cells to help fight AML that has returned or not responded to standard therapy. The goal is to see if these cells can safely and effectively control the leukemia.
This trial tests a new type of immune cell therapy that uses your own cells, modified to attack leukemia cells in multiple ways. It aims to find a safe and effective dose for people with acute myeloid leukemia who have not responded to other treatments.
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
This trial tests a new immune cell therapy for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy uses your own cells, modified to target cancer cells, and may help when other treatments haven't worked.
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.